Pages that link to "Q48009721"
Jump to navigation
Jump to search
The following pages link to Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. (Q48009721):
Displaying 26 items.
- Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site (Q24555099) (← links)
- Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors (Q24650641) (← links)
- Pharmacology of the calcium sensing receptor (Q26860064) (← links)
- Cinacalcet versus standard treatment for chronic kidney disease: a protocol for a systematic review and meta-analysis (Q28079300) (← links)
- Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors (Q28362372) (← links)
- Calcium-sensing receptor inhibits secretagogue-induced electrolyte secretion by intestine via the enteric nervous system (Q28565175) (← links)
- Functional expression of the extracellular calcium sensing receptor (CaSR) in equine umbilical cord matrix size-sieved stem cells (Q33855728) (← links)
- High Extracellular Ca2+ Stimulates Ca2+-Activated Cl− Currents in Frog Parathyroid Cells through the Mediation of Arachidonic Acid Cascade (Q33895196) (← links)
- Calcium-sensing receptor and aquaporin 2 interplay in hypercalciuria-associated renal concentrating defect in humans. An in vivo and in vitro study (Q34189805) (← links)
- Calcium-sensing receptor abrogates secretagogue- induced increases in intestinal net fluid secretion by enhancing cyclic nucleotide destruction (Q34665224) (← links)
- Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics (Q34795759) (← links)
- Pharmacological evidences for the stimulation of calcium-sensing receptors by nifedipine in gingival fibroblasts. (Q35052349) (← links)
- Secondary hyperparathyroidism disease stabilization following calcimimetic therapy (Q35573653) (← links)
- The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis (Q35826159) (← links)
- Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets (Q36662050) (← links)
- Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies (Q36947025) (← links)
- Activation of the Ca²+-sensing receptor induces deposition of tight junction components to the epithelial cell plasma membrane (Q37309886) (← links)
- Effects of cinacalcet treatment on QT interval in hemodialysis patients (Q37672944) (← links)
- Calcium-sensing receptor: a high-affinity presynaptic target for aminoglycoside-induced weakness (Q39568405) (← links)
- Allosteric modulation of the calcium-sensing receptor (Q40179229) (← links)
- Vascular actions of calcimimetics: role of Ca²(+) -sensing receptors versus Ca²(+) influx through L-type Ca²(+) channels. (Q41832147) (← links)
- Three-year successful cinacalcet treatment of secondary hyperparathyroidism in a patient with x-linked dominant hypophosphatemic rickets: a case report (Q41977160) (← links)
- A subthreshold persistent sodium current mediates bursting in rat subfornical organ neurones (Q50106711) (← links)
- Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet (Q57216887) (← links)
- Use of calcimimetics in children with normal kidney function (Q88093857) (← links)
- Foreword (Q94376106) (← links)